Shareholders Rebel Against Connetics
The suit was the third of its kind filed in the U.S. District Court for the Northern District of California alone. Like the others, it accused the pharmaceutical company of keeping stock prices artificially inflated by failing to disclose a 2004 study that showed the drug caused tumors in 55% of mice.
Then, as they continued stating that Velac...
To view the full article, register now.